Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intuba...
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
Yale University, New Haven, Connecticut, United States
Parkland Health & Hospital System, Dallas, Texas, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memoral Sloan Kettering Westchester, Harrison, New York, United States
University on Missouri Hospital, Columbia, Missouri, United States
WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States
Department of Anesthesiology and Pain Medicine, Seoul, Korea, Republic of
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
Melbourne Health, Parkville, Victoria, Australia
Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia
The Royal Womens Hospital, Parkville, Victoria, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.